LLY · Eli Lilly and Company
AI read · Good for LLY
The AI's read
Calytrix's drug targets a specific blood disease, but it is still being tested. Lilly also reported weight and health improvements across several drug studies. Those results support Lilly's future treatment options, though the deal commits cash and some payments depend on later milestones.